================================================================================
CLINICAL TRIALS PERFECT MATCHES REPORT (ULTRA-STRICT CRITERIA)
================================================================================

Patient ID: 1
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
01/2017 V.a. neue Lebermetastase
02/2017 Start Somatoline
02/2018 CT Abdomen: stable disease
03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. 
Clinical Question: Weitere Therapie?
Report generated: 2025-07-14 15:50:16

Found 6 relevant clinical trials
--------------------------------------------------------------------------------

1. PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
   NCT ID: NCT03365791
   Status: COMPLETED
   Phase: PHASE2
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically includes a cohort for "Advanced well-differentiated neuroendocrine tumors." The patient has a well-differentiated NET (G1) of the small intestine with metastatic disease, aligning perfectly with the cohort description. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient’s tumor is G1, and has metastasized to lymph nodes and the liver – fitting the “advanced” criteria within the study. While Ki-67 isn’t provided, ...
   Condition: Small Cell Lung Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Castration Resistant Prostate Adenocarcinoma; Soft Tissue Sarcoma; Ovarian Adenocarcinoma; Advanced Well-differentiated Neuroendocrine Tumors; Diffuse Large B Cell Lymphoma
   Intervention: PDR001; LAG525
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2018-01-24
   Completion Date: 2020-09-17
   Locations: California Pacific Medical Center Drug Shipment (2), San Francisco, United States; Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, United States; University Cancer and Blood Center, LLC, Athens, United States
   URL: https://clinicaltrials.gov/study/NCT03365791
   Summary: The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
----------------------------------------

2. A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
   NCT ID: NCT05459844
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** Exact match. The study specifically targets GEP-NETs (Gastroenteropancreatic Neuroendocrine Tumors), and the patient has a NET of the duodenum (small intestine – a GEP site) with liver metastases. This aligns perfectly. 2. **Tumor Characteristics:** The patient’s tumor was initially G1. The study stratification includes G1 and G2 NETs, therefore the patient’s grade is compatible. The patient has metastatic disease (liver metastases), which is appropriate for this study d...
   Condition: Neuroendocrine Tumors
   Intervention: Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR
   Sponsor: Sinotau Pharmaceutical Group
   Start Date: 2022-08-31
   Completion Date: 2028-12
   Locations: Chinese PLA General Hospital, Beijing, China; The First Afilliated Hospital of Fujian Medical University, Fuzhou, China; The First Affiliated Hospital of Xiamen University, Xiamen, China
   URL: https://clinicaltrials.gov/study/NCT05459844
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2)...
----------------------------------------

3. Open-Label Surufatinib in European Patients With NET
   NCT ID: NCT04579679
   Status: COMPLETED
   Phase: PHASE2
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically includes a cohort (Cohort B) for NET of small bowel origin, which perfectly matches the patient’s diagnosis of a small bowel NET (Dünndarm NET). This is a precise anatomical match. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The study targets low- to intermediate-grade (G1 or G2) well-differentiated NETs. The patient’s initial tumor was G1. While there's mention of possible progression in 2019, the study *allows* for...
   Condition: Neuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NET
   Intervention: Surufatinib
   Sponsor: Hutchmed
   Start Date: 2021-08-13
   Completion Date: 2024-10-15
   Locations: University of Alabama, Birmingham (UAB), Birmingham, United States; University of California Irvine Medical Center UCIMC - H.H. Chao Comprehensive Digestive Disease Center CDDC, Orange, United States; Emory University, Winship Cancer Institute, Atlanta, United States
   URL: https://clinicaltrials.gov/study/NCT04579679
   Summary: This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
----------------------------------------

4. Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
   NCT ID: NCT05359146
   Status: RECRUITING
   Phase: EARLY_PHASE1
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically targets neuroendocrine neoplasms (NENs), and the patient has a well-defined small bowel NET (Dünndarm NET) with metastases. This aligns perfectly with the study’s inclusion criteria. The study focuses on gastroenteropancreatic NETs (GEP-NETs), which encompasses the patient’s small bowel primary. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient’s initial tumor was G1. While the current status regarding grade is...
   Condition: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
   Intervention: 161Tb-DOTA-LM3; 177Lu-DOTATOC
   Sponsor: University Hospital, Basel, Switzerland
   Start Date: 2023-03-28
   Completion Date: 2025-12
   Locations: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
   URL: https://clinicaltrials.gov/study/NCT05359146
   Summary: The goal of this phase 0 proof-of concept study is to measure the therapeutic index (tumour to dose-limiting-organ dose ratios) of 161Tb-DOTA-LM3 in comparison to the current standard 177Lu-DOTATOC in the same gastroenteropancreatic neuroendocrine tumour (GEP-NET) patients in a randomized, cross-ove...
----------------------------------------

5. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically targets GEP-NETs, and the patient has a well-documented small intestine NET (SI-NET), a subtype of GEP-NET. The location (duodenum/ileum) is directly relevant. The study focuses on improving surgical resection of these tumors, aligning with the patient's situation. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient’s initial tumor was G1. While the current status indicates possible progression, the study doesn’t...
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
----------------------------------------

6. Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
   NCT ID: NCT06784752
   Status: RECRUITING
   Phase: PHASE3
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** Exact match. The study specifically targets Grade 1 and Grade 2 Advanced GEP-NETs. The patient has a Grade 1 NET of the small intestine (Dünndarm) with metastatic disease, fitting the study’s inclusion criteria perfectly. No broader cancer types are mentioned. 2. **Tumor Characteristics:** Perfect alignment. The patient’s tumor is a Grade 1 NET with metastatic disease to the liver and lymph nodes. The study explicitly includes Grade 1 and Grade 2 tumors. While progressio...
   Condition: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
   Intervention: [177Lu]Lu-DOTA-TATE; Octreotide LAR
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2025-05-30
   Completion Date: 2034-01-05
   Locations: Highlands Oncology Group, Fayetteville, United States; Rocky Mountain Cancer Centers, Denver, United States; Piedmont Hematology And Oncology, Winston-Salem, United States
   URL: https://clinicaltrials.gov/study/NCT06784752
   Summary: The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<...
----------------------------------------